Zalutumumab in head and neck cancer

Bibliography

• Jemal A, Siegel R, Ward E Murray T, Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66
   PubMed Web of Science ®Google Scholar
• Hauswald H, Simon C, Hecht S, Long-term outcome and patterns of failure in patients with advanced head and neck cancer. Radiat Oncol 2011;6:70
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Lavertu P, Saxton JP, Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000;88:876-83
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Zouhair A, Azria D, Ozsahin M. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 2006;1:11
   PubMed Web of Science ®Google Scholar
• Hitt R, Ciruelos E, Amador ML, Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005;41:453-60
   PubMed Web of Science ®Google Scholar
• Chung CH, Ely K, McGavran L, Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Pathak HB, Lokshin AE, Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009;113:21-7
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Paulus R, Curran WJ, Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011;29:2312-18
   PubMed Web of Science ®Google Scholar
• Merchan JR, Ferrell A, Macintyre J, Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Am J Clin Oncol 2011; published online 5 May 2011; doi: 10.1097/COC.0b013e31821862fb
   Google Scholar
• Han SW, Oh DY, Im SA, Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009;100:298-304
   PubMed Web of Science ®Google Scholar
• Neyns B, Sadones J, Joosens E, Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009;20:1596-603
   PubMed Web of Science ®Google Scholar
• Schiller JH, von Pawel J, Schutt P, Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5:1977-85
   PubMed Web of Science ®Google Scholar
• Hecht JR, Patnaik A, Berlin J, Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-8
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Hecht JR. Panitumumab in colorectal cancer. Expert Rev Anticancer Ther 2007;7:967-73
   PubMed Web of Science ®Google Scholar
• Rao S, Starling N, Cunningham D, Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010;21:2213-19
   PubMed Web of Science ®Google Scholar
• You B, Brade A, Magalhaes JM, A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs 2011;29:996-1003
   Google Scholar
• Wirth LJ, Allen AM, Posner MR, Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010;21:342-7
   PubMed Web of Science ®Google Scholar
• Crombet T, Osorio M, Cruz T, Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54
   PubMed Web of Science ®Google Scholar
• Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008;3:1157-71
   PubMedGoogle Scholar
• Lammerts van Bueren JJ, Bleeker WK, Brannstrom A, The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 2008;105:6109-14
   PubMed Web of Science ®Google Scholar
• Kastner J, Loeffler HH, Roberts SK, Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics. J Struct Biol 2009;167:117-28
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren JJ, Bleeker WK, Bogh HO, Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006;66:7630-8
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004;173:4699-707
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, van den Brakel JH, Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 2011;187:3383-90
   PubMed Web of Science ®Google Scholar
• Bastholt L, Specht L, Jensen K, Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2007;85:24-8
   PubMed Web of Science ®Google Scholar
• Machiels JP, Subramanian S, Ruzsa A, Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase III trial. Lancet Oncol 2011;12:333-43
   PubMed Web of Science ®Google Scholar
• Noordhuis MG, Eijsink JJ, Ten Hoor KA, Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 2009;15:7389-97
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7
   PubMed Web of Science ®Google Scholar
• Herbst RS, Arquette M, Shin DM, Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87
   PubMed Web of Science ®Google Scholar
• Baselga J, Trigo JM, Bourhis J, Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77
   PubMed Web of Science ®Google Scholar
• O'Neil BH, Allen R, Spigel DR, High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007;25:3644-8
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008;358:1109-17
   PubMed Web of Science ®Google Scholar
• Rivera F, Salcedo M, Vega N Blanco Y, Lopez C. Current situation of zalutumumab. Expert Opin Biol Ther 2009;9:667-74
   PubMed Web of Science ®Google Scholar
• Van Walle I, Gansemans Y, Parren PW, Immunogenicity screening in protein drug development. Expert Opin Biol Ther 2007;7:405-18
   PubMed Web of Science ®Google Scholar